cecCONCEPTS
HEALTHCARE EDUCATION

TARGETING THE PATHWAY

Evolving Roles of MEK Inhibitors in NF1-Associated PN

Friday, November 21, 2025
5:15–6:15 PM HST

Doors open: 5:00 PM
Hawaii Convention Center
Room 323BC

TARGETING THE PATHWAY

Evolving Roles of MEK Inhibitors in NF1-Associated PN

Activity Description

Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder characterized by tumor predisposition and a wide spectrum of neurologic manifestations. Among its most serious complications are plexiform neurofibromas (PNs), which can cause significant morbidity due to pain, disfigurement, neurologic impairment, and risk of malignant transformation. Despite advances in understanding NF1 biology, care remains complex and often fragmented across specialties, leading to delayed recognition and limited access to evolving therapies. Recent clinical evidence has established MEK inhibitors as targeted therapeutic options for NF1-associated PNs. Incorporating these therapies into practice requires careful patient selection, safety monitoring, and interprofessional coordination to ensure optimal outcomes.

This CE Concepts live symposium will address these critical gaps by equipping neuro-oncologists, neurosurgeons, radiation oncologists, medical oncologists, advanced practitioners, and nurses with strategies for early recognition of NF1-associated tumors, effective integration of MEK inhibitors, and development of evidence-based, interprofessional care plans that support individualized, longitudinal management.

Target Audience

Neuro-oncologists, neurosurgeons, radiation oncologists, medical oncologists, physician associates (PAs), nurse practitioners (NPs), and nurses

Financial Support

This program is supported through an independent educational grant from Alexion Pharmaceuticals.

Faculty

Jaishri Blakeley
MD (Co-Chair)

Angela Hirbe
MD, PhD (Co-Chair)

Darren Hargrave
MB.Chb (Hons), MD, MRCP, FRCPCH

Learning Objectives

At the conclusion of this activity, learners will be able to better:

- Assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making
- Integrate MEK inhibitors in the management of NF1-associated PNs in adult and pediatric patients
- Develop evidence-based, interprofessional care plans for patients with NF1 that reflect current clinical standards and support individualized, longitudinal management

The Society for Neuro-Oncology has reviewed and approved this symposium as appropriate for presentation as an Independent Supported Symposium. The symposium constitutes the content and views of the sponsor and is not part of the official SNO Annual Meeting program.

© 2025 CE CONCEPTS. ALL RIGHTS RESERVED.

TARGETING THE PATHWAY

Evolving Roles of MEK Inhibitors in NF1-Associated PN

Accreditation

Jointly Accredited Provider

In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME)

Creative Educational Concepts, LLC, designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC)

This activity is designated for 1.0 contact hours.

Pharmacotherapy: ANCC definition of pharmacotherapeutic content is that it may include but is not limited to drug specific information, safe prescribing practices, safe medication administration, prescribing methodologies, new regulations, or similar content.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Oncology Nursing Certification (ONCC) [ILNA]

This activity is designated for 1.0 contact hours. The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

Physician Assistants (AAPA)

Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

RCP Canada

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

MIPS

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

EACCME UEMS

Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use *AMA PRA Category 1 Credit*™ toward their credit requirements. Creative Educational Concepts is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

© 2025 CE CONCEPTS. ALL RIGHTS RESERVED.

TARGETING THE PATHWAY

Evolving Roles of MEK Inhibitors in NF1-Associated PN

Faculty



Jaishri Blakeley

MD (Co-Chair)

Professor of Neurology, Neurosurgery and Oncology

The Marjorie Bloomberg Tiven
Professor of Neurofibromatosis

Executive Director, Neurofibromatosis Therapeutic Acceleration Program

Director, Johns Hopkins Comprehensive Neurofibromatosis Program

The Johns Hopkins University School of Medicine

Baltimore, MD

Dr. Jaishri Blakeley is a clinician scientist with a clinical practice focused on the care of individuals with NF1, the schwannomatoses, and primary brain cancers. Her research expertise is in the development of clinical trials for nervous system tumors including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints in efficacy studies. She is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology and Neurosurgery at Johns Hopkins School of Medicine, Director of the Johns Hopkins Comprehensive Neurofibromatosis Center, and Executive Director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). NTAP aims to accelerate effective treatments for NF1-related plexiform and cutaneous neurofibromas and growing the NF1 field via a focus on collaboration across academia, industry, and government entities, open and timely sharing of results, and streamlined approaches to support research. Dr. Blakeley is also an active member in the NF Clinical Trials Consortium and leader of several NF-focused clinical trials.

© 2025 CE CONCEPTS. ALL RIGHTS RESERVED.

TARGETING THE PATHWAY

Evolving Roles of MEK Inhibitors in NF1-Associated PN

Faculty



Angela Hirbe

MD, PhD (Co-Chair)

Associate Professor of Medicine and Pediatrics
Director, Adult Neurofibromatosis Clinical Program
Division of Oncology, Sarcoma Section
Washington University School of Medicine
St. Louis, MO

Angela Hirbe, MD, PhD, is a practicing medical oncologist who treats sarcoma. Her research focuses on utilization of genomic information from sarcomas to better understand the pathogenesis of these tumors and to identify biomarkers and therapeutic targets for these aggressive cancers.

© 2025 CE CONCEPTS. ALL RIGHTS RESERVED.

TARGETING THE PATHWAY

Evolving Roles of MEK Inhibitors in NF1-Associated PN

Faculty



Darren Hargrave

MB.Chb (Hons), MD, MRCP, FRCPCH

Clinical Professor in Paediatric Neuro-Oncology
University College London Great Ormond Street Institute of Child Health
Honorary Consultant Paediatric Oncologist
Great Ormond Street Hospital for Children
London, UK

Darren Hargrave, MB.Chb (Hons), MD, MRCP, FRCPCH, is a full professor of Paediatric Neuro-oncology at University College London and Honorary Consultant Paediatric Oncologist at Great Ormond Street Hospital, London UK where he leads the Neuro-oncology and Experimental Therapeutics programme since 2011. Prior to this following training in UK and Canada he was appointed in 2002 as Consultant Paediatric Oncologist where he developed the South Thames Paediatric Neuro-oncology and Drug Development programmes. He has been the Chief Investigator of over 20 Clinical Trials from “first in child” to large Randomised International Phase III studies. He is the current Chair of the UK NCRI Children’s Cancer Group was previously the Vice-Chair of the Paediatric Experimental Cancer Medicine Network and Chair of the European SIOPe Paediatric Brain Tumour Group. He serves on multiple National and European Childhood Cancer organisations including UK NCRI, CRUK and ITCC committees. He has acted as an external scientific advisor/reviewer for the US Pediatric Brain Tumor Consortium (PBTC), NIH and the French Cancer Agency. He is the Co-chair with Maryam Fouladi of the Collaborative Network of Neuro-Oncology Clinical Trials (CONNECT), an international consortium of 18 leading academic paediatric neuro-oncology centres. He has extensive experience in translational research, development and coordination of clinical trials and leadership of clinical research teams and networks. He has been the Paediatric Oncologist associated with the NHS Complex Neurofibromatosis Type-1 Service for over 15 years and recently joined the EU PEARL Consortium to develop novel therapies for children with NF1 associated tumours.

© 2025 CE CONCEPTS. ALL RIGHTS RESERVED.

TARGETING THE PATHWAY

Evolving Roles of MEK Inhibitors in NF1-Associated PN

Disclosure Declarations

It is the policy of Creative Educational Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. Creative Educational Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Faculty

Dr. Blakeley reports the following financial relationships:

Consultant: Alexion Pharmaceuticals, Inc. and SpringWorks Therapeutics, Inc.

Research Support: Bristol Myers Squibb Company

Dr. Hirbe reports the following financial relationships:

Advisory Board: Aadi Subsidiary, Inc.

Consultant: Aadi Subsidiary, Inc.; Alexion Pharmaceuticals, Inc.; AstraZeneca; and SpringWorks Therapeutics, Inc.

Grants: Tango

Other financial or material support: Boehringer Ingelheim

Dr. Hargrave reports the following financial relationships:

Advisory Board and Consultant: Alexion Pharmaceuticals, Inc./ AstraZeneca; Day One Biopharmaceuticals, Inc.; Ipsen Pharma; Novartis; and SpringWorks Therapeutics, Inc.

Grants: Alexion/AstraZeneca

Speakers Bureau: Alexion Pharmaceuticals, Inc./AstraZeneca; Ipsen Pharma; and SpringWorks Therapeutics, Inc.

Peer Reviewers

Alaa Bawaneh, MD, PhD–no disclosures to report.

Jessica Giddens, DNP, APRN, FPMHNP-BC, RN-BC–no disclosures to report.

CMEO Staff/Planners

Thomas Mitchell, MSW, LSW–no disclosures to report.

Nichole Lainhart–no disclosures to report.

David Modrak, PhD–no disclosures to report.

Alexis Oneca–no disclosures to report.

Scott J. Hershman, MD, FACEHP, CHCP–no disclosures to report.

Sandra Caballero, PharmD–no disclosures to report.

Sharon Tordoff–no disclosures to report.

All identified conflicts of interest have been mitigated.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

© 2025 CE CONCEPTS. ALL RIGHTS RESERVED.

TARGETING THE PATHWAY

Evolving Roles of MEK Inhibitors in NF1-Associated PN

Instructions for Interactive Technology

Use one of the iPads provided at your table to answer polling questions, view onsite presentations, and submit questions to the faculty. Please see additional information below.

Ask Faculty a Question

Select the Ask Question tab below the slide viewer to submit a question. If your question is for a specific faculty member, please include their name. Your question will be shared with the faculty for the question-and-answer portion of the session.

View and Take Notes on Presentation Slides

Select the Take Notes tab to take notes during the meeting. All of the notes you take during the meeting will be emailed to the address provided within 5 business days.

Obtaining Credit

To receive CME/CE credit for this activity, scan the QR code to login to or create a learner account.

Downloadable Resources

Downloadable resources will be available at **ceconcepts.com/targetingresources**.

Engage with Us

Follow us **@ceconcepts** for announcements about upcoming CME opportunities, health care news, and more!

Thank you for joining us today!

ceCONCEPTS HEALTHCARE EDUCATION

© 2025 CE CONCEPTS. ALL RIGHTS RESERVED.